Литекатура на тему: Современная терапия рекуррентного депрессивного расстройства: от научных исследований к клинической практике


Литература

  1. Артаментова Л. А., Филипцова О. В. Введение в психогенетику. М. 2004, С. 357
  2. Аведисова А. С. Ремиссия: новая цель терапии и новые методы ее оценки//Психиатрия и психофармакотер. 2004; Т. 6, № 4, с. 156-158.
  3. Беляев Б. С. Аффективный эндогенный психоз (клиника, патогенез, систематика). Автореф. дисс. на соиск. учен. степ. докт. мед. наук. М., 1989, с. 51.
  4. Вартанян М. Е. Современные проблемы генетики психиатрических заболеваний// Проблемы медицинской генетики: сб. ст.- М., 1970, с. 495-509.
  5. Вовин Р.Я., Скорик А. И., Аксенова И. О., Дигилов А. Г. Эффективность финлепсина при профилактической терапии фазно-протекающих аффективных психозов//Журн. невропатол. и психиатр, им. С. С. Корсакова, 1987, № 9, с. 1396-1400.
  6. Вовин Р.Я. Вторичная профилактика карбамазепином аффективных нарушений при эндогенных психозах//Антиконвульсанты в психиатрической и неврологической практике. С.-П6., 1994, с. 50-72.
  7. Ганнушкин П. Б., Суханов С. А. К учению о меланхолии//Журн. невропатол. и психиатрии, 1902, Кн. 6, с. 1170-1187.
  8. Каннабих Ю. В. История психиатрии//Гос.Мед. Изд., Ленинград., 1928, с. 429-430
  9. Каспер С. Обоснование длительной терапии антидепрессантами//Соц. Психиатрия 1995, № 1, с. 80-91.
  10. Киселев А. С., Сочнева 3. Г. Закономерности начала, течения и исходов основных психических заболеваний (статистическое исследование). — Рига: Зинатне, 1988, с. 236.
  11. Костюкова Е.Г. Карбамазепин как средство профилактики рецидивов аффективных и шизоаффективных психозов//Дисс.на соиск. учен.степ. канд. мед. наук. — М., 1989, с. 165.
  12. Мосолов С. Н. Клиническое применение современных антидепрессантов//Медицинское информационное агенство, С.-П6., 1995.
  13. Нуллер Ю.Л., Михайленко И.Н. Аффективные психозы//Из-во Ленинград, 1985, с. 115.
  14. Сарториус Н., Багай X, Баррет Б. и др. Терапия антидепрессантами и другие методы лечения депрессивных расстройств. Доклад Рабочей группы CINP на основе обзора доказательных данных. Москва, 2008, с. 34.
  15. Тювина Н. А., Крук Я. В. Сравнительное исследование эффективности амитриптилина, финлепсина и коаксила при профилактической терапии рекуррентного депрессивного рас-стройства//Психиатр. и психофармакотер, 2005, Т. 7, № 3, с. 160-164.
  16. Altamura С. A., Percudani М. The use of antidepressants for long-tearm treatment of recurrent depression: rationale, current methodologies and future directions//J. Clin Psychiatry; 1993, Vol. 54 (suppl. 8), p.29-38.
  17. Anderson I. M. SSRI versus tricyclic antidepressants indepressed inpatient: a meta-analisis of efficacy and tolerability//Depress Anxiety.1998, Vol. 7 (suppl. 1), p. 11—17.
  18. Anderson I. M. Selective serotonin reaptake inhibitor versus tricyclic antidepressants: a meta-analisis of efficacy and tolerability//J. Affect. Disord. 2000, Vol. 58, p.19-36.
  19. Anderson I.M., Meta-analytical studies on new antidepressants//Br. Med. Bull., 2001, Vol. 57, p. 161—178.
  20. Angst J. Zur Aetiologie und Noslogie endogener depressiver Psychosen//Monogr Gesamtgeb Neurol Psychiatr/Berlin, Springer, 1966, Vol. 112, p. 1-118.
  21. Angst J. Verlauf unipolar depressiver, bipolar manisch-depressiver und schizoaffektive Erkrankungen und Psychosen. Ergebnisse einer prospektiven Studie. Fortschr//Neurol. Psychiat., 1980, Bd.48, p.3-30.
  22. Angst J., Preisig M. Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985//Schweiz. Arch. Neurol. Psychiatr. 1995, Vol. 146, № 1, p.17-23.
  23. Bauer M., Whybrow P. C., Angst J. et al. World federation of societies of biological psychiatry guidelines for biological treatment of unipolar depressive disorder//The world journal of biological psychiatry; 2002, Vol. 3, № 2, p.69-86.
  24. Benkert O., Grunder G., Wetzel H., Hackett D. A randomized, doubleblind comparison of rapidly escalating dose of venlafaxine and imipramine in patients with major depression and melancholia//J Psychiat Res., 1996, Vol. 30, p. 441451.
  25. Berrettini, W., Ferraro, T, Choi, H. et al. Linkage studies of bipolar illness//Archives of General Psychiatry, 1997, Vol. 54, p.32-39.
  26. Burgess S., Geddes J., Hawton K. et al. Lithium for maintenance treatment of mood disorders (Cochrane Rewiew). In Cochrane Library, 2001, Issue 3. Update Software, Oxford
  27. Carney M., Roth M., Garside R. The diagnosis of depressive syndromes and the prediction of ECT response//Br. J. Psychiatry. 1965, Vol. Ill, p.659-674.
  28. Cassano G. B., Maggini C., Longo E. Depressions//Encephale, 1979, Vol. 5, fasc.5 (suppl.), p.449-458.
  29. Cipriani A., Barbui C., Brambilla R, Furukava T. A., Hotorf M., Geddes J. R. Are all antidepressants really the same? The case of fluoxetine: a systematic review//J. Clin. Psychiatry. 2006, Vol. 67, p.850-864.
  30. CiprianiA., Furukawa T. A., Geddes J. R. et al. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and metaanalysis//J. Clin. Psychiatry. 2009, Vol. 69, p.1732-1742.
  31. Claghorn J. L., Feighner J. P A double-blind comparison of paroxetine with imipramine in the long-treatment of depression//J. Clin. Psychopharmacology 1993, Vol. 11, p.45-67.
  32. Coppen A., Chose K., Montgomery S., Bailey J. E., Jorgensen A. Continuation therapy with amitriptyline in depression//Brit.J. Psychiat. 1978, Vol. 133, p.28-33.
  33. 33.Costa e Silva J. A. Facing depression//WPA Teaching Bulletin on Depression, 1993, Vol. 1, № l.p. 1.
  34. Deshauer D. Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose//CMAJ, 2007, Vol. 176, p.39-40.
  35. Doogan D. P., Caillard V. Sertraline in prevention of deprcssion//Brit.J. Psychiat 1992, Vol. 160, p.217-222.
  36. Dunner D. L., Gershon E. S., Goodwin F. K. Heritable factors in the severity of affectine illness//Biol. Psychiatry, 1976, Vol. 11, p.31-42.
  37. Fava M. Pharmacological approaches to the treatment of residual symptoms//J Psychopharmacol., 2006, Vol. 20, p.29-34.
  38. Fieve R. R., Dunner D. I., Kumbarachi T, Stallone F. Lithium carbonate in affective disoders. A double-blind study of prophylaxis in unipolar recurrent depression//Arch. Gen. Psychiatry, 1976, Vol. 32, № 12, p.1541-1544.
  39. Franchini L., Gasperini M., Perez J. et al. Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, double-blind study//J. Clin. Psychiatry, 1998, Vol. 59, № 5, p.229-232.
  40. Frank E., Kupfer D.J. et al. Three-year outcome for maintenance therapies in recurrent depression//Arch. Gen. Psychiatry, 1990, Vol. 47, p.1093-1099.
  41. Gartlehner G., Thieda R, Hansen R. A. et al. Comparative risk for harms of second generation antidepressants: a systematic review and meta-analysis//Drug Safety, 2008, Vol. 31, p.851-865.
  42. Gilaberte I., Montejo A. L., de la Gandara J. et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study//J. Clin. Pharmacologycal, 2001, Vol. 21, p. 417-424.
  43. Glen A. I. M., Jonson A. L., Shepherd M. Continuathion therapy with Lithium and Amitriptyline in unipolar depressive illness: A randomized double-blind controlled trial//Psychol. Med. 1984, Vol. 14, p.37-50.
  44. Goodwin F. K., Jamison K. R. Manic-Depressive Illness. 1990. New York, Oxford University Press.
  45. Goodwin G., Rouillon E, Emsly R. Long-term treatment with agomelatine: prevention of relapse in patients with MDD over 10 months//Eur. Neuropsypharmacol., 2009, Vol. 18, p.338.
  46. Hamilton M. A rating scale for depression//J. Neurol. Neurosurg. Psychiat., 1960, p.56-62.
  47. Hirschfeld R. M. Guidelines for the long-term treatment of depression//J. Clin. Psychiatry., 1994, Vol. 55, suppl. 12, p.61-69.
  48. Hirschfeld R. M. The long-term nature of depression//Psychiatr. Ann., 1996, Vol. 26, p.313-314.
  49. 49.Hirschfeld R. M. Clinical importance of long-term antidepressant treatment//Br. J. Psychiatry, 2001, Vol. 42, p.4-8.
  50. Hochstrasser B., Isaksen P. M., Koponen H. et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy//Brit.J. Psychiat. 2001, Vol. 178, p.294-295.
  51. Israel J. A. Remission in depression: definition and treatment approaches//J. Psychopharm acol., 2006, Vol. 20, p.5-10.
  52. Judd L. L. The clinical course of unipolar major depressive disorders//Archives of General Psychiatry, 1997, Vol. 54, p.989-991.
  53. Judd L. L., Akiskal H. S., Maser J. D. et al. Major depressive disorder: a prospective study of residual subtreshold depressive symptoms as predictor of rapid relapse//J Affect Disord. 1998, Vol. 50, p.97-108.
  54. Judd, L. L., Akiskal H. S., Maser J. D. et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders//Arch. Gen. Psychiatry. 1998, Vol. 55, p.694-700.
  55. Judd L. L., Paulus M.J., Schettler P.J. et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?//Am. J. Psychiatry, 2000, Vol. 157, p.1501-1504.
  56. Kasper S. Jahreszeit und Befindlichkeit in der Allgemeinbevo’ lkerung. Eine Mehrebenenuntersuchung zur Epidemiologie, Biologie und therapeutischen BeeinfluCbarkeit (Lichttherapie) saisonaler Befindlichkeitsschwankungen. Monographien aus dem Gesamtgebiet der Psychiatrie/Springer, Berlin, 1991, Vol. 66, p. 1-118
  57. Kennedy S. H., Lamb R.W., Parikh S. V. et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adult//Journal of Affective Disorders, 2009, Vol. 117, p. 1-2.
  58. Kinkelin M. S. Verlauf und Prognose des manisch-depressiven Irreseins//Schweiz Arch. Neurol. Psychiat., 1954, Vol. 73, N° 1, p. 100-46.
  59. Kishimoto A., Mizukawa R. et al. Prophylactic effect of mianserin of recurrent depression// Acta Psychiat. Scand, 1994, Vol. 89, № 1, p.46-51.
  60. Kraepelin E. Manic-depressive illness. History of a syndrom//International Univ. Press, Neew York, 1997, p.9-33.
  61. Kupfer D.J. Long-term treatment of depression//}. Clin. Psychiatry, 1991, Vol. 52 (suppl. 5), p. 28-34.
  62. Kupfer D.J., Frank E., Perel J. M. Five-year outcome for maintenance therapies in recurrent depression//Arch. Gen. Psychiat. 1992, Vol. 49, p.769-773.
  63. Lam R. W. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherap//Joumal of Affective Disorders, 2009, Vol. 117, p.26-43.
  64. Laux G., Koenig W., Pfaff G. Pharmacopsychiatria 1988, Vol. 21, p. 87-92.
  65. Leonhard K. Die cycloiden, meist als Schizophrenien verkannten Psychosen//Psychiatr. Neurol. Psychol., 1957, Bd.12, p.359-365.
  66. Loke Y. K., Trivedi A.N., Singh, S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs//Aliment. Pharmacol. Ther., 2008, Vol. 27, p. 31-40.
  67. Moll E., Neuman N., Schmid-Burgk W. et al. Safety and efficacy during long-term treatment with Moclobemide//Clin. Neuropharmocol., 1994, Vol. 17, № 1 (Suppl. 1), p. 74-87.
  68. Montgomery S. A., Asberg M: A new depression scale designed to be sensitive to change// British Journal of Psychiatry, 1979, Vol. 134, p. 382-389.
  69. Montgomery S. A., Dufour H., Brien S., Gailledreau J., Lequeille X., Ferrey G. C et al. The prophylactic of fluoxetine in unipolar depression//Brit.J. Psychiat. 1988, Vol. 140, p.76-82.
  70. Montgomery S. A., Green. M., Baldwin D//Prophilactic Treatment of depression: A public health issue//Neuropsychobiology, 1989, Vol. 22, p.216.
  71. Montgomery S. A., Doogan D. P, Burnside R. The influence of different relapse criteria on assessment of the long-term efficacy of sertraline//Int Clin Psychopharmacol., 1991. Vol. 6 (Suppl. 2), p.37-46.
  72. Montgomery S. A., Dunbar G.J. Paroxetine is better tolerated then plaecbo in relapse prevention and the prophylaxis of recurrent depression//Clin. Psychopharmacology, 1993, Vol. 8, p.189-195.
  73. Montgomery S. A., Reimitz P. E., Zivkov M. Mirtazapine versus amitriptiline in the long-term treatment of depression: a double-blind placebo-controlled study//Int. Clin.Psychopharmacology, 1998, Vol. 13, p.63-73.
  74. Montgomery S. A., Baldwin D. S., Blier P, Fineberg N. A., Kasper S., Lader M., Lam R. W., Lepine J. P, Moller H.J., Nutt D.J., Rouillon R, Schatzberg A. E, Thase M. E., Which antidepressants have demonstrated superior ef cacy? A review of the evidence//Int. Clin. Psychopharmacol., 2007, Vol. 22, p.323-329.
  75. Montgomery S., Cutler A., Lazarus A. et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of patients with major depressive disorder (MDD)//16th European Congress of Psychiatry; Nice, France. 2008.
  76. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London, NICE, 2004.
  77. Nemeroff С. B., Entsuah R., Benattia I. et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs//Biol. Psychiatry, 2008, Vol. 63, p.424-443.
  78. Nierenberg A. A., Bronwyn R. K., Vinita C. L. et al. Residual symptoms in depressed patients who respond acutely to fluoxetine//J. Clin. Psychiatry, 1999, Vol. 60, p.221-225.
  79. Ohrberg S., Christiansen P. E., Severin B. et al. PUroxetine and imipramine in the treatment of depressive patients in psychiatric practice//Acta Psychiatr Scand., 1992, Vol. 86, № 6, p.437-444.
  80. Papakostas G. I., Perlis R. H., Scalia M. J., Petersen T. J., Fava M. A metaanalysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder//J. Clin. Psychopharmacol. 2006, Vol. 26, p.56-60.
  81. Paykel E. S., Ramana Z., Cooper H. et al. Residual symptoms after partial remission: an important outcome in depression//Psychol Med. 1995, Vol. 25, p.l 171—1180.
  82. Paykel E. Basic concepts of depression//Dialogues in Clinical Neuroscience, 2008, Vol. 10, №3.
  83. Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses// Acta Psychiatr Scand, 1966, Vol. 42, p.189-194.
  84. Placidi G. F., Lenzi A., Lazzerini F. The comparative efficacy and safety of oarbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients//J. Clin. Psychiatry, 1986, Vol. 47, p.490-494.
  85. Prien R. E, Klett С. H., Caffey E. M. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness//Arch. Gen. Psychiatry, 1973, Vol. 29, № 3, p.420-425.
  86. Ramana R., PUycel E. S., Cooper Z. Remission and relapse in major depression: a two-year prospective follow-up study//Psychol. Med., 1995, Vol. 25, p.l 161—1170.
  87. Raskin J., Goldstein D.J., Mallinckrodt C.H. et al. Duloxetine in the long-term treatment of major depressive disorder//J. Clin. Psychiatry, 2003, Vol. 64, p.1237-1244.
  88. Raymond W. L., Sidney H., Kennedy S. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy//Journal of Affective Disorders, 2009, Vol. 117, p. 26-24.
  89. Reimherr F. W., Amsterdam J. D. et al. Prospective Assessment During Long-Term Fluoxetine Treatment//Am. J. Psychiatry, 1998, Vol. 155, p.1247-1253.
  90. Rouillon F. et al. Prophylactic efficacy of maprotiline on unipolar depression relapse//J. Clin. Psychiat. 1991, Vol. 52, N2 10, p.423-431.
  91. SartoriusN., Baghai T. C., Baldwin D. S. et al. Antidepressant Medications and Other Treatments of Depressive Disorders: A CINP Task Force Report Based on a Review of Evidence// The International Journal of Neuropsychopharmacology, 2007, Vol. 10 (suppl. 1).
  92. Sergeant J. K., Bruce M. L., Florio L. P. et al. Factors associated with 1-year outcome of major depression in the community//Arch. Gen. Psychiatry, 1990, Vol. 47, p. 510-515.
  93. Simhandl C., Denk E., Thau K. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders//J. Affect Disord, 1993, Vol. 28, p.221-231.
  94. Souza F. G., Goodwin G. M. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis//Br. J. Psychiatry, 1991, Vol. 158, p. 666-675.
  95. Stassen H. H., Delini-Stula A., Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach//Eur Neuropsychopharmacol. 1993, Vol. 3, № 2, p.127-135.
  96. Taylor M.J., Freemantle N., Geddes J. R., Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis//Arch. Gen. Psychiatry, 2006, Vol. 63, p. 1217-1223
  97. Terra J. L., Montgomery S. A. Fluoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study//Int. Clin. Psychopharmacology, 1998, Vol. 13, p.55-62
  98. Thase M. E., Rush A.J. When at first you don’t succeed: sequential strategies for antidepressant nonresponders//J. Clin. Psychiatry. 1997, Vol. 58, p.23-29
  99. Thase M. E. Achieving remission and managing relapse in depression//J. Clin. Psychiatry. 2003, Vol. 64 (suppl. 18), p. 3-7.
  100. Tylee A. Depression in Europe: experience from DEPRES II survey//Europ. Psychychopharm., 2000, Vol. 10 (suppl. 4), p. 445-448
  101. Wade A., Friis A. H. The onset of effect for escitalopram and its relevance for the clinical management of depression//Curr. Med. Res. Opin. 2006, Vol. 22, p. 2101-2110
  102. Warden D., Rush A.J., Madhukar H. et al. The Star*D Project results. A comprehensive reviev of findings//Curr Psychiatry Rep. 2007, Vol. 9, p. 449-459.
  103. Weihs K. L., Hauser T. L., Batey S. R. et al. Continuation phase treatment with bupropion effectively decreases the riak for relapse of depression//Biol. Psychiatry 2002, Vol. 51, № 9, p.753-759
  104. WHO Mental Health Collaborating Centres. Parmacotherapy of. depressive disorders. A consensus statement//J. Affect Dis, 1989, Vol. 17, p.197—198

Если вы нашли ошибку, пожалуйста, выделите фрагмент текста и нажмите Ctrl+Enter.